肝爽颗粒对新型组织工程肝脏非酒精性脂肪性肝病大鼠模型脂代谢的影响

张译之; 段钟平; 张晓慧; 陈煜

doi:10.3969/j.issn.1001-5256.2020.07.020

肝爽颗粒对新型组织工程肝脏非酒精性脂肪性肝病大鼠模型脂代谢的影响

DOI: 10.3969/j.issn.1001-5256.2020.07.020

首都医科大学附属北京佑安医院疑难肝病及人工肝中心，肝衰竭与人工肝治疗研究北京市重点实验室

基金项目:

北京市自然科学基金(7202070)；国家重点研发计划资助(2017YFA0103000)；国家科技重大专项“艾滋病和病毒性肝炎等重大传染病防治”(2017ZX10203201-005,2017ZX10201201-001-001,2017ZX10201201-002-002,2017ZX10201201-004-002,2017ZX10202203-006-001,2017ZX10302201-004-002)；北京市医院管理局临床医学发展专项经费资助(ZYLX201806)；中国肝炎防治基金会天晴肝病研究基金(TQGB20200101)；国家自然科学基金(81500472)；

详细信息

中图分类号: R575.5
计量
- 文章访问数: 1385
- HTML全文浏览量: 69
- PDF下载量: 158
- 被引次数: 0
出版历程
- 出版日期: 2020-07-20

Effect of Ganshuang granules on lipid metabolism in a new tissue-engineering model of nonalcoholic fatty liver disease

Intractable Hepatic Diseases and Artificial Liver Treatment & Training Center, Beijing YouAn Hospital, Capital Medical University；Beijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research; Beijing 100069, China

Research funding:

摘要

摘要: 目的探讨肝爽颗粒（GSG）干预对新型组织工程肝脏非酒精性脂肪性肝病（NAFLD）模型脂代谢的影响及其机制。方法将Sprague Dawley大鼠肝脏去细胞化制为肝脏胶原支架,用人Hep G2细胞对支架再细胞化,从而获得组织工程（TE）肝（正常对照组）,用含游离脂肪酸（FFA）的高脂培养基灌注TE肝建立NAFLD模型（FFA组）,该模型进一步用GSG浸膏处理后为FFA+GSG组。比较各组肝脏TG含量及丙酮酸脱氢酶激酶4（PDK4） mRNA水平;比较FFA组和FFA+GSG组脂代谢相关酶mRNA表达情况,并行油红O染色评估肝脏病理学。计量资料组间差异比较采用t检验。结果 FFA组TG含量较正常对照组显著升高（t=4. 842,P=0. 004 7）,FFA组PDK4 mRNA水平较正常组显著升高（t=2. 784,P=0. 031 8）; FFA+GSG组较FFA组细胞内TG水平显著下降（t=0. 055,P=0. 003 7）,PDK4表达显著降低（t=3. 761,P=0. 009 4）;脂肪酸转位酶、脂肪酸结合蛋白1、ATP柠檬酸裂解酶、乙酰辅酶A羧化酶、脂肪酸合成酶、脂肪酸去饱和...
- 非酒精性脂肪性肝病 /
- 组织工程 /
- 肝爽颗粒 /
- 大鼠,Sprague-Dawley
Abstract: Objective To investigate the effect of Ganshuang granules( GSG) intervention on lipid metabolism in a new tissue-engineering model of nonalcoholic fatty liver disease( NAFLD) and its mechanism. Methods The liver of Sprague-Dawley rats was decellularized into collagen scaffolds,and human HepG2 cells were used to recellularize the scaffolds to obtain the tissue-engineering( TE) liver as normal control group. The TE liver was perfused with high-fat medium containing free fatty acid( FFA) to establish a model of NAFLD( FFA group),and this model was further treated with GSG extract to establish a FFA + GSG group. These groups were compared in terms of the content of triglyceride( TG) and the mRNA expression of PDK4 in the liver,and the mRNA expression of enzymes associated with lipid metabolism was compared between the FFA group and the FFA + GSG group; oil red O staining was used to evaluate liver pathology. The t-test was used for comparison of continuous data between groups. Results Compared with the normal control group,the FFA group had significantly higher content of TG( t = 4. 842,P = 0. 004 7) and mRNA expression of PDK4( t = 2. 784,P = 0. 031 8). Compared with the FFA group,the FFA + GSG group had significant reductions in the content of TG in cells( t = 0. 055,P = 0. 003 7),the expression of PDK4( t = 3. 761,P = 0. 009 4),and the mRNA expression of fatty acid translocase,fatty acid-binding protein 1,ATP citrate lyase,acetyl-CoA carboxylase,fatty acid synthase,fatty acid desaturase 2,1-acylglycerol-3-phosphate O-acyltransferase 5,and apolipoprotein B( t = 6. 552,4. 944,2. 689,4. 524,6. 040,3. 758,4. 443,and 3. 032,P = 0. 007 2,0. 001 1,0. 027 6,0. 020 2,0. 009 1,0. 005 6,0. 047 1,and 0. 016 3). Oil red O staining showed significant reductions in the number of lipid droplets in hepatocytes and the degree of hepatocyte fatty degeneration. Conclusion GSG can reduce the intake of FFA,the de novo synthesis of fatty acid,and the generation and deposition of TG in hepatocytes in the model of NAFLD and thus improve dyslipidemia.
- nonalcoholic fatty liver disease /
- tissue engineering /
- Ganshuang granule /
- rats,Sprague-Dawley

HTML全文

参考文献(25)

[1]National Workshop on Fatty Liver and Alcoholic Liver Disease,Chinese Society of Hepatology,Chinese Medical Association;Fatty Liver Expert Committee,Chinese Medical Doctor Association.Guidelines of prevention and treatment for nonalcoholic fatty liver disease:A 2018update[J].J Clin Hepatol,2018,34(5):947-957.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组，中国医师协会脂肪性肝病专家委员会．非酒精性脂肪性肝病防治指南(2018年更新版)[J]．临床肝胆病杂志，2018,34(5):947-957．

[2]DIEHL AM,DAY C.Cause,pathogenesis,and treatment of nonalcoholic steatohepatitis[J].N Engl J Med,2017,377(21):2063-2072．

[3]MASARONE M,FEDERICO A,ABENAVOLI L,et al.Non alcoholic fatty liver:Epidemiology and natural history[J].Rev Recent Clin Trials,2014,9(3):126-133．

[4]SHU JR,LI JQ,LIU Q.Analysis of epidemiology and risk factors of nonalcoholic fatty liver disease[J].J Clin Hepatol,2019,35(9):2085-2090.(in Chinese)舒筠然，李俊琪，刘琼．非酒精性脂肪性肝病的流行病学和危险因素分析[J]．临床肝胆病杂志，2019,35(9):2085-2090．

[5]ZHANG Y,WANG H,ZHANG L,et al.Codonopsis lanceolata polysaccharide CLPS alleviates high fat/high sucrose diet-induced insulin resistance via anti-oxidative stress[J].Int J Biol Macromol,2020,145:944-949．

[6]GÓMEZ-ZORITA S,MILTON-LASKIBAR I,AGUIRRE L,et al.Effects of pterostilbene on diabetes,liver steatosis and serum lipids[J].Curr Med Chem,2019.[Online ahead of print]

[7]YANG SZ,XU SX,DONG L,et al.Ganshuang granules alleviates non-alcoholic steatohepatitis in rats[J].J Shanxi Med Univ,2016,47(3):205-210.(in Chinese)杨素贞，许绍娴，董蕾，等．肝爽颗粒对大鼠非酒精性脂肪性肝炎的治疗作用[J]．山西医科大学学报，2016,47(3):205-210．

[8]SUN HQ,WANG XQ,SHI HB,et al.Ganshuang granules protect mouse liver from chronic injury induced by CCl4via autophagy[J].Chin J Clin Hepatol,2015,31(7):1114-1119.(in Chinese)孙海青，王小琪，时红波，等．肝爽颗粒对CCl4诱导的慢性肝损伤小鼠模型和肝损伤细胞模型的保护作用[J]．临床肝胆病杂志，2015,31(7):1114-1119．

[9]KANG WW,ZHOU L,DANG SS,et al.Multi center clinical study on the treatment of chronic hepatitis B with Ganshuang Granules[J].China J Tradit Chin Med Pharma,2017,32(12):5689-5693.(in Chinese)康玮玮，周莉，党双锁，等．肝爽颗粒治疗慢性乙型肝炎的多中心临床研究[J]．中华中医药杂志，2017,32(12):5689-5693．

[10]WEI SN,SU XY,XU GH.Anomaly of triglyceride metabolism in liver lead to NAFLD[J].Chin J Biochem Mol Biol,2016,32(2):123-132.(in Chinese)魏苏宁，苏雪莹，徐国恒．肝细胞甘油三酯代谢途径异常与脂肪肝[J]．中国生物化学与分子生物学报，2016,32(2):123-132．

[11]SHI H,SHI H,REN F,et al.Naringin in Ganshuang Granule suppresses activation of hepatic stellate cells for anti-fibrosis effect by inhibition of mammalian target of rapamycin[J].J Cell Mol Med,2017,21(3):500-509．

[12]BYRNE CD,TARGHER G.NAFLD:A multisystem disease[J].JHepatol,2015,62(1 Suppl):s47-s64．

[13]COBBINA E,AKHLAGHI F.Non-alcoholic fatty liver disease(NAFLD)-pathogenesis,classification,and effect on drug metabolizing enzymes and transporters[J].Drug Metab Rev,2017,49(2):197-211．

[14]SANYAL AJ.Past,present and future perspectives in nonalcoholic fatty liver disease[J].Nat Rev Gastroenterol Hepatol,2019,16(6):377-386．

[15]ASGHARPOUR A,CAZANAVE SC,PACANA T,et al.A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer[J].J Hepatol,2016,65(3):579-588．

[16]WU Q,LIU J,LIU LJ,et al.Establishment of an ex Vivo model of nonalcoholic fatty liver disease using a tissue-engineered liver[J].ACS Biomater-Sci Eng,2018,4(8):3016-3026．

[17]DONNELLY KL,SMITH CI,SCHWARZENBERG SJ,et al.Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease[J].J Clin Invest,2005,115(5):1343-1351．

[18]KOO SH.Nonalcoholic fatty liver disease:Molecular mechanisms for the hepatic steatosis[J].Clin Mol Hepatol,2013,19(3):210-215．

[19]HAN WJ,LIU S,DUAN ZP,et al.Molecular mechanism of hepatocyte steatosis in non-alcoholic fatty liver disease[J].Chin J Gastroenterol Hepotol,2018,27(10):1103-1109.(in Chinese)韩伟佳，刘霜，段钟平，等．非酒精性脂肪性肝病中肝细胞脂肪变性分子机制的研究[J]．胃肠病学和肝病学杂志，2018,27(10):1103-1109．

[20]di PIETRO SM,SANTOMEJA.Structural and biochemical characterization of the lungfish(Lepidosiren paradoxa)liver basic fatty acid binding protein[J].Arch Biochem Biophys,2001,388(1):81-90．

[21]MAO J,DEMAYO FJ,LI H,et al.Liver-specific deletion of acetyl-Co A carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis[J].Proc Natl Acad Sci U S A,2006,103(22):8552-8557．

[22]DORN C,RIENER MO,KIROVSKI G,et al.Expression of fatty acid synthase in nonalcoholic fatty liver disease[J].Int J Clin Exp Pathol,2010,3(5):505-514．

[23]AVRAMOGLU RK,BASCIANO H,ADELI K.Lipid and lipoprotein dysregulation in insulin resistant states[J].Clin Chim Acta,2006,368(1-2):1-19．

[24]KOTZKA J,MULLER-WIELAND D.Sterol regulatory elementbinding protein(SREBP)-1:Gene regulatory target for insulin resistance?[J].Expert Opin Ther Targets,2004,8(2):141-149．

[25]DUVNJAK M,LEROTIC'I,BARSIC'N,et al.Pathogenesis and management issues for non-alcoholic fatty liver disease[J].World J Gastroenterol,2007,13(34):4539-4550.

施引文献

资源附件(0)

访问统计